Noninvasive Cancer Diagnostics: Technologies and Global Markets

  • ID: 4385420
  • Report
  • Region: Global
  • 335 Pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 7
The Global Market for Noninvasive Cancer Diagnostics Was Valued at $107.4 Billion in 2016

FEATURED COMPANIES

  • 20/20 Gene Systems
  • Biocartis N.V.
  • Cepheid Inc.
  • Genomic Health
  • Integragen S.A.
  • Quantumdx
  • MORE

Report Includes:

  • An overview of the global noninvasive cancer diagnostics market.
  • Analyses of global market trends, with data from 2016, estimates for 2017 and projections of compound annual growth rates (CAGRs) through 2022.
  • Analysis of the market by principle technology and by geography.
  • Detailed breakdown of advanced non-invasive approaches.
  • Coverage of segmentation of the cell-free DNA diagnostic methods.
  • A look at major factors driving the growth of the non-invasive cancer diagnostic and technologies market.
  • Profiles of major players in the industry.

Report Scope:

The aim of this report is to initially conduct a review of the noninvasive cancer diagnostics products currently available; assess the market potential by clinical application; examine statistics on the incidence and mortality of cancer; review the issues facing the use of noninvasive cancer diagnostics; and review some of the latest developments into new and innovative noninvasive cancer diagnostic products, their technologies, and their intended clinical applications.

Key objectives are to conduct and provide an analysis of the market value, growth rates, market shares, and market development, as well as examine the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with:

A detailed analysis of the revenues and forecasts for the global noninvasive cancer diagnostics market with a further, more detailed analysis and forecast of the revenues for the global market subdivided by major market subsegments by geographic region and finally by selected country.
A detailed analysis of the global market share, together with a further, more detailed analysis of the market share by geographic region and finally by selected country.

Key Highlights:

  • The global market for noninvasive cancer diagnostics was valued at $107.4 billion in 2016. This market is estimated to grow from nearly $114.6 billion in 2017 to $159.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.
  • Diagnostic imaging technologies, the leading segment of this market, will grow from $43.6 billion in 2017 to $58.5 billion by 2022 with a CAGR of 6.1%.
  • The market for advanced noninvasive approaches will grow from $40.5 billion in 2017 to $57.9 billion by 2022 with a CAGR of 7.4%.

In addition, this analysis provides a:

  • Detailed review of the current products, their indications and availability for all the market segments identified.
  • Profile of the individual market subsegments within the major market segments analyzed and the distinguishing features of each of the market subsegments.
  • Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
  • Brief description of the historical development for each of the major market segments.
  • Profile of the leading suppliers of noninvasive cancer diagnostics and related products, together with related information about specific products.

The study will allow the reader to:

  • Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the noninvasive cancer diagnostics market.
  • Investigate the current market dynamics that are driving change in the noninvasive cancer diagnostics market.
  • Assess future growth opportunities in the noninvasive cancer diagnostics market.
  • Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
  • Utilize the report to help realize a company’s position in the marketplace and to provide insight into the future of the market and the opportunities that exist.
READ MORE
Note: Product cover images may vary from those shown
2 of 7

FEATURED COMPANIES

  • 20/20 Gene Systems
  • Biocartis N.V.
  • Cepheid Inc.
  • Genomic Health
  • Integragen S.A.
  • Quantumdx
  • MORE

Chapter 1: Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Methodology and Information Sources
  • Primary Data and Information Gathering
  • Secondary Data and Information Gathering
  • Market Share Analysis and Market Forecast Prediction
  • Geographic Breakdown
  • Analyst's Credentials
  • Related Reports

Chapter 2: Summary and Highlights

  • Summary of Key Findings
  • Diagnostic Imaging Segment
  • Advanced Diagnostics Segment
  • Conventional Segment

Chapter 3: Market and Technology Review: Diagnostic Imaging

  • Real-time In Vivo Cancer Diagnosis using Raman Spectroscopy
  • In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics
  • Direct Imaging
  • Indirect Fluorescence Imaging
  • Magnetic Resonance Imaging (MRI) Scans
  • Development to the RF Subsystem
  • Positron Emission Tomography (PET) Scan
  • Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
  • Mammography
  • Digital Mammography Systems
  • Breast Tomosynthesis Systems
  • Ultrasound
  • Barium Swallow or Enema
  • Bone Scans (MRI, CT and PET)
  • Market Estimate

Chapter 4: Market and Technology Review: Advanced Noninvasive Cancer

  • Diagnostic Assays and Technologies
  • Introduction to Circulating Nucleic Acids (CNAs)
  • Circulating Nucleic Acids as a Diagnostic Tool
  • Circulating DNA as a Biomarker of Cancer
  • Use of Circulating DNA for Prenatal Diagnosis (Conventional)
  • Use of Circulating DNA for Prenatal Diagnosis (Noninvasive)
  • Circulating RNA as a Biomarker of Cancer
  • Methods Used for the Detection of Circulating Nucleic Acids
  • Liquid Biopsy
  • Janssen Diagnostics
  • Roche Molecular Systems Inc.
  • Genomic Health
  • Foundation Medicine
  • Veracyte
  • Trovagene Inc.
  • Myriad Genetics
  • OncoCyte Corp.
  • Illumina
  • NeoGenomics Laboratories
  • Biocept Inc.
  • Vermillion Inc.
  • Sysmex Inostics, a subsidiary of Sysmex Corp.
  • Guardant Health
  • Product Development and New Initiatives in Liquid Biopsy
  • Molecular Cytogenetic/Gene Expression Studies
  • Amplify and Detect Diminished Amounts of RNA Consistently
  • Analyze Hundreds of Genes
  • Proteomics and New Protein Markers
  • Inside the ProteinChip System
  • Proteome Pattern Recognition
  • Next-Generation Sequencing (NGS) Studies
  • Illumina Solexa System
  • Roche 454 Sequencing
  • Thermo Fisher Scientific Ion Personal Genome Machine (PGM)
  • Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection)
  • Oxford Nanopore Technologies
  • The Third-Generation Sequencer
  • Clinical Acceptance of a New Diagnostic Assay
  • Saliva-Based Oral Cancer Diagnostics
  • Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH))
  • Optical Biopsy
  • Market Estimate

Chapter 5: Market and Technology Review: Conventional Noninvasive Cancer

  • Diagnostic Assays and Tests
  • Pap Test and HPV Testing
  • Tumor Biomarker Testing
  • MammaPrint Specifications
  • Genomic Health’s Oncotype DX Breast Cancer Test
  • The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test)
  • Sales and Marketing Strategies for Cancer Tests
  • Fecal Occult Blood Tests (FOBT)
  • Digital Rectal Exam (DRE)
  • Multigated Acquisition (MUGA) Scans
  • Market Estimate

Chapter 6: Incidence, Prevalence and Mortality Statistics for Cancer: A Global

  • Summary
  • Cancer: The Disease
  • Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
  • Incidence and Prevalence Rates for Major Cancer Types
  • Regional Patterns of Cancer
  • Europe
  • North America
  • Asia-Pacific
  • Latin and Central America
  • Middle East/Africa
  • The Global Cancer Burden and Worldwide Cancer Risk Factors
  • Tobacco Use and Statistics
  • Alcohol Abuse and Cancer Statistics
  • Obesity and Cancer Statistics
  • Infectious Diseases and Cancer
  • Inherited Genes/Diseases and Cancer
  • Sun, U.V. and Cancer
  • Hormones and Cancer

Chapter 7: Noninvasive Cancer Diagnostics Market by Cancer Type

  • Global Noninvasive Cancer Diagnostics Market, by Cancer Type
  • Global Market Drivers
  • Global Market Restraints
  • Regional Noninvasive Cancer Diagnostics Market Assessment: North America
  • Selected Market Drivers: North America
  • Selected Market Restraints: North America
  • Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Europe
  • Selected Market Drivers: Europe
  • Selected Market Restraint: Europe
  • Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Asia-Pacific
  • Selected Market Drivers: Asia-Pacific
  • Selected Market Restraints: Asia-Pacific
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America
  • Selected Market Drivers: Central and Latin America
  • Selected Market Restraints: Central and Latin America
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa
  • Selected Market Drivers: Middle East/Africa
  • Selected Market Restraints: Middle East/Africa

Chapter 8: Market Analysis by Technology, End User and Market Share

  • Global Noninvasive Cancer Diagnostics Market, by Technology
  • Regional Noninvasive Cancer Diagnostics Market, by Technology: North America
  • Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe
  • Regional Noninvasive Cancer Diagnostics Market, by Technology: Asia-Pacific
  • Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America
  • Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa
  • Global Noninvasive Cancer Diagnostics Market, by End-User
  • General Clinical Reference Laboratories
  • Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market

Chapter 9: Technological Advances, Trends and Opportunities

  • Key Technological Developments and Advances, Market Trends and Opportunities
  • Developments and Advances, Trends and Opportunities in Diagnostic Imaging
  • Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches
  • Developments and Advances, Trends and Opportunities in Screening Assays
  • Opportunities for IVDMIA Companies

Chapter 10: Regulatory and Legislative Requirements

  • United States
  • How are IVDs Classified?
  • FDA Regulations Relating to Companion Diagnostics
  • Laboratory Developed Tests (LDTs)
  • Centers for Medicare & Medicaid Services (CMS)
  • The 2010 Affordable Care Act
  • Private Insurance
  • Europe
  • (General) Medical Device Directive, MDD (93/42/EEC)
  • Active Implantable Medical Device Directive, AIMDD (90/383/EEC
  • In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)
  • Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC)
  • Japan
  • Marketing Authorization System
  • China
  • Overview of the Healthcare System
  • Healthcare Reforms
  • Healthcare Institutions
  • India
  • Overview of the Healthcare System
  • Hospital Resources
  • Population Statistics
  • South Korea
  • Brazil
  • Background
  • Regulatory and Legislative Requirements
  • Market Entry and Reimbursement of Medical Devices: Brazil
  • Argentina
  • Background
  • Government-funded Public Health Sector
  • Social Health Insurance Sector
  • Private Sector
  • Regulatory and Legislative Requirements
  • Mexico
  • Legislation and Regulations Governing Medical Devices in Mexico
  • Health Insurance Structure in Mexico

Chapter 11: Patent Review of Key Technologies

  • Microarray Patents
  • LOAC Patents
  • Clinical Next-Generation Sequencing (NGS) Patents
  • Clinical NGS Patents Summary
  • Clinical NGS Patents by Indication

Chapter 12: Company Profiles

  • Appendix A: Company Addresses and Contact Details
  • Appendix B: Government Regulatory Agencies and Professional Organizations
  • Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer
  • Diagnostics

List of Tables:
Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 1 Diagnostic Imaging Segment
Table 2 Advanced Segment
Table 3 Conventional Segment
Table 4 Noninvasive Cancer Diagnostics Market Segmentation
Table 5 Breast MRI Systems Currently Available
Table 6 Wide Bore MRI Systems Currently Available
Table 7 PET/CT Systems Currently Available
Table 8 PET/MR Systems Currently Available
Table 9 Key trends in (Digital Mammography Systems)
Table 10 Digital Mammography Systems Currently Available
Table 11 Breast Tomosynthesis Systems Currently Available
Table 12 Benefits of Medical Ultrasound Imaging
Table 13 Regulatory Approval for High-intensity Focused Ultrasound (HIFU) by Region
Table 14 Ultrasound Systems Currently Available
Table 15 Noninvasive Cancer Diagnostics Market Segmentation
Table 16 Major Developments in Understanding Nucleic Acids and their Cellular Roles
Table 17 Circulating Tumor-associated miRNAs as Potential Cancer Biomarkers
Table 18 Key Elements for Business Competition in Gene Expression Profiling for Cancer
Table 19 DNA Microarray Diagnostic Test Adoption Rate
Table 20 Characteristics of in situ Hybridization Methods
Table 21 Key Advantages of Optical Biopsy Systems
Table 22 Noninvasive Cancer Diagnostics Market Segmentation
Table 23 Key Drivers to Adoption of Biomarkers in Clinical Use
Table 24 Key Barriers to Adoption of Biomarkers in Clinical Use
Table 25 Tumor Biomarkers Currently in Common Clinical Use
Table 26 MammaPrint: Key Features
Table 27 Strategies for Marketing Cancer Diagnostic Products
Table 28 Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
Table 29 Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
Table 30 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence, 2012
Table 31 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (In Men and Women Combined) by Cancer Type, 2012
Table 32 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Men) by Cancer Type, 2012
Table 33 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Women) by Cancer Type, 2012
Table 34 Estimated Number of New Cancer Cases by Sex: United States, 2017 (%)
Table 35 Estimated Number of Deaths from Cancer by Sex: United States, 2017
Table 36 Global Noninvasive Cancer Diagnostics Market, Through 2022 ($ Millions)
Table 37 Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 38 Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)
Table 39 Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 40 North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 41 Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing
Table 42 United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 43 Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 44 European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 45 Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Table 46 France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 47 Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 48 Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 49 Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 50 U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 51 Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 52 Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 53 Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 54 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 55 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 56 China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 57 India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
Table 58 Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
Table 59 South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 60 Rest of Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 61 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 62 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Table 63 Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 64 Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 65 Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 66 Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 67 Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 68 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 69 Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 70 Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 71 Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 72 Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 73 Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 74 Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 75 Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening and Diagnostic Assays and Tests Technology, Through 2022 ($ Millions)
Table 76 North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 77 North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 78 North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 79 North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 80 Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 81 Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 82 Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 83 Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 84 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 85 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 86 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 87 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 88 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 89 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 90 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 91 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 92 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 93 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 94 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 95 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 96 Global Noninvasive Cancer Diagnostics Market, by End-User, Through 2022 ($ Millions)
Table 97 Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 98 Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 99 Global Market Share for Molecular Signature-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 100 Global Market Share for DNA Microarray-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 101 Global Market Share for Cytogenetic/Gene Expression-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 102 Global Market Share for Circulating Nucleic Acid (CNA)-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 103 Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 104 Global Market Share for Fecal Occult Blood Test (FOBT)-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 105 Global Market Share for Tumor Biomarker Test-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 106 Principal Factors Influencing the Growth and Development of Noninvasive Cancer Diagnostics, 2017
Table 107 Uses of Tumor Biomarkers in Drug Development
Table 108 Utility of Biomarkers as Companion Diagnostics to Drug Development
Table 109 Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature (JMDN) Codes and Related Codes according to the EU MDD
Table 110 Number of Healthcare Institutions According to Ownership in China, 2010
Table 111 Total Number of Hospitals by Ranking in China, 2010
Table 112 Overview of Healthcare in India
Table 113 DNA Microarray Patents by Region, 2002-2012
Table 114 Microarray-Related Proteomics Patents by Region, 2002 - 2012
Table 115 Microarray-Related Patents by Application and Title, 2017
Table 116 Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 - Present
Table 117 LOAC-Related Proteomics Patents by Region, 2002 - 2012
Table 118 LOAC-Related Patents by Application and Title, 2013 - 2015
Table 119 Clinical Next Generation Sequencing Patents, 2002-2012
Table 120 Clinical NGS-Related Patents by Application and Title, 2013 - 2015
Table 121 Clinical NGS Patents by Indication, 2002-2012
Table 122 Abbott Laboratories: Company Financials, Through 2016 ($ Millions)
Table 123 Bayer AG: Company Financials, Through 2016 ($ Millions)
Table 124 bioMerieux S.A. Sales by Application, Through 2016 ($ Millions)
Table 125 Exact Sciences Corp.: Company Financials, Through 2016 ($ Millions/%)
Table 126 Hologic Inc.: Company Financials, 2015-2016 ($ Millions)
Table 127 Illumina, Inc: Company Financials, 2014-2016 ($ Millions)
Table 128 Myriad Genetics Inc. Financials, 2014 - 2016 ($ Millions)
Table 129 Philips Healthcare Financials, Through 2016 ($ Millions)
Table 130 Philips Group Financials by Segment, 2016 ($ Millions)
Table 131 Qiagen N.V. Financials, Through 2016 ($ Millions)
Table 132 Qiagen N.V. Financials by Region, Through 2016 ($ Millions)
Table 133 Quest Diagnostics Financials, Through 2016 ($ Millions)
Table 134 Roche Group Financials, Through 2016 ($ Millions) - 322
Table 135 Diagnostics Division Financials, 2015 and 2016 ($ Millions)
Table 136 Thermo Fisher Scientific Inc. Financials, Through 2016 ($ Millions)
Table 137 Company Addresses and Contact Details
Table 138 Government Regulatory Agencies and Professional Organizations Associated with Noninvasive Cancer Diagnostics
Table 139 Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics

List of Figures:
Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 2016-2022 ($ Millions)
Figure 1 Top Molecular CNA Characterization Techniques (%)
Figure 2 Market Growth and Evolution of MDx Cancer Biomarkers
Figure 3 Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined, 2012 (%)
Figure 4 Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%)
Figure 5 Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%)
Figure 6 Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%)
Figure 7 Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Figure 8 Average Number of New Cases per Year and Age-Specific Incidence Rates for all Cancers in the U.K., 2012?2014
Figure 9 Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 10 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 11 Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 12 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Figure 13 Global Noninvasive Cancer Diagnostics Market, by Technology Type, 2016-2022 ($ Millions)
Figure 14 Global Noninvasive Cancer Diagnostics Market, by End-User, 2016-2022 ($ Millions)
Figure 15 Tumor Biomarker Developments and Market Applications (%)
Figure 16 Private Health Insurance Coverage among Persons Under 65 in United States, 2007-2011 (Millions/Percent)
Figure 17 The Chinese Healthcare System

Note: Product cover images may vary from those shown
3 of 7

Loading
LOADING...

4 of 7

FEATURED COMPANIES

  • 20/20 Gene Systems
  • Biocartis N.V.
  • Cepheid Inc.
  • Genomic Health
  • Integragen S.A.
  • Quantumdx
  • MORE

Analyst Credentials:

Paul Taylor is an independent market researcher and analyst focused on the medical industry. He previously worked for multinational medical device companies on strategic business and marketing plans. His predictive analytics knowledge and models of market research data have been used for biopharmaceutical and biotechnology clients. He has a bachelor's degree and Ph.D. degree in biochemistry from the University of Liverpool and an MBA degree for Oxford Brookes University.

Note: Product cover images may vary from those shown
5 of 7
  • 20/20 Gene Systems
  • Abbott Laboratories
  • Adaptive Biotechnologies Inc.
  • Advanced Cell Diagnostics Inc. (Bio-Techne Corp.)
  • Agena Bioscience Inc.
  • Almac Group
  • Andor Technology Ltd. (Oxford Instruments PLC)
  • Asuragen Inc.
  • Autogenomics Inc.
  • Bayer Healthcare
  • Biocartis N.V.
  • Biocept Inc.
  • Biodesix Inc.
  • Biomerieux, S.A.
  • Biotheranostics Inc.
  • Boreal Genomics
  • Cancer Genetics Inc.
  • Cepheid Inc.
  • Chronix Biomedical
  • Combimatrix Molecular Diagnostics Inc.
  • Epigenomics
  • Exact Sciences Corp.
  • Exiqon A/S
  • Exosome Diagnostics Inc.
  • General Electric Co.
  • Genomic Health
  • Guardant Health
  • Hitachi Medical Corp.
  • Hologic Inc.
  • Ikonisys Inc.
  • Illumina Inc.
  • Insight Genetics Inc.
  • Integragen S.A.
  • Mindray
  • Myriad Genetics Inc.
  • Oncocyte Corp.
  • Oxford Gene Technology (OGT)
  • Pathway Genomics Corp.
  • Personal Genome Diagnostics
  • Philips Healthcare Co.
  • Qiagen N.V.
  • Quantumdx
  • Quest Diagnostics
  • Roche Molecular Systems Inc.
  • Rosetta Genomics Inc.
  • Samsung Medison
  • Siemens
  • Sonosite Inc. (Fujifilm)
  • Thermo Fisher Scientific Inc
  • Toshiba Corp.
  • Trovagene
  • Verisante Technology Inc.
  • Volcano Corp. (Philips Medical)
Note: Product cover images may vary from those shown
6 of 7
7 of 7
Note: Product cover images may vary from those shown
Adroll
adroll